ArticleAnalytical cellular pathology (Amsterdam)2025
Clinicopathological Features and Immunochemical Staining of Inflammatory Myofibroblastic Tumor: A Retrospective Study of 48 Cases.
Article in Analytical cellular pathology (Amsterdam), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Single-Site ALK-Positive Histiocytosis With TFG-ALK Fusion: Expanding the Clinical Spectrum of This Rare Entity.The American journal of case reports · 2026Article
- Smooth muscle actin (SMA)-negative uninodular plexiform fibromyxoma: case report of a challenging atypical presentation of a rare gastric mesenchymal tumor in a 25-year-old female.AME case reports · 2026Article
- Case report: Reactive nodular fibrous pseudotumor: report of 4 new cases including a rare pulmonary presentation and a literature review covering 40 cases.Frontiers in medicine · 2026Article
- Clinicopathological Features and Immunochemical Staining of Inflammatory Myofibroblastic Tumor: A Retrospective Study of 48 Cases.Analytical cellular pathology (Amsterdam) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory myofibroblastic tumors (IMTs) are rare neoplasms found in diverse anatomical sites, including the lungs, intestines, and bladder. Surgical resection is the primary treatment, with chemotherapy offering survival rates of 21.2 and 42.5 months in unresectable cases. Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have emerged as standard treatments. However, IMT presents diagnostic challenges owing to its morphological similarities with other conditions. While positive ALK expression aids diagnosis in approximately 50% of the cases, negative ALK expression complicates diagnosis. This retrospective study reviewed 48 patients with IMT diagnosed at a Taiwanese medical center and analyzed their clinical characteristics, pathology reports, immunohistochemical (IHC) staining profiles, and outcomes. Chi-square and independent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.